Research programme: kinase inhibitors - Plexxikon

Drug Profile

Research programme: kinase inhibitors - Plexxikon

Alternative Names: Omni-Raf inhibitors - Plexxikon; PLX-FK1; PLX4720

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Plexxikon
  • Developer OncoSec Medical; Plexxikon
  • Class Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto-oncogene protein b-raf modulators; Raf kinase inhibitors; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cancer; Inflammation; Malignant melanoma; Multiple sclerosis; Polycystic kidney disease

Most Recent Events

  • 15 Apr 2016 Preclinical development for Multiple sclerosis and Alzheimer's disease is ongoing in USA
  • 18 Nov 2014 Plexxikon and OncoSec Medical enter into a preclinical collaboration to evaluate combination immunotherapy for Cancer, including malignant melanoma
  • 18 Nov 2014 Preclinical trials in Malignant melanoma (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top